Froome facing questions over adverse test result

Chris Froome is facing questions after returning an “adverse” drugs test at the Vuelta a Espana.
The Team Sky rider had double the allowed level of legal asthma drug Salbutamol in his urine.
Cycling’s world governing body, the UCI, wants more details from the team but says Froome is not suspended.
The Briton, 32, says he increased his dosage but it was within the legal limits and the UCI is “absolutely right” to ask questions.
Froome says he took his team doctor’s advice to up his inhaler use after his asthma symptoms got worse during the Vuelta.
He became the first Briton to win the three-week race around Spain and it followed his Tour de France victory in July.
He was notified of the “adverse analytical finding” on  September 20 2017.
The urine test, taken on  September 7, showed levels of the drug, Salbutamol, which is commonly taken for asthma, were at 2,000 nanograms per millilitre (ng/ml).
That compares to the World Anti-Doping Agency’s (Wada) threshold of 1,000 ng/ml.
The use of Salbutamol is permitted, without the need of a therapeutic use exemption (TUE), but only within certain doses.
No other samples taken from Froome during the race needed further examination. (BBC Sport)